Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevidalen in Alzheimer's Disease
NCT06538116Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of mevidalen in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Integrated Alzheimer's Disease Rating Scale at Week 24. Started Aug 2024; status: completed.
02
Drugs
mevidalen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06538116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538116.